Ertumaxomab: A trifunctional antibody for breast cancer treatment

Expert Opinion on Investigational Drugs

Volumn 17, Issue 10, 2008, Pages 1553-1558

  Kiewe, Philipp ^a   Thiel, Eckhard ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bispecific antibody; Breast cancer; CD3; HER 2 neu; Immunotherapy; Trifunctional antibody

Indexed keywords

CATUMAXOMAB; CD3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERTUMAXOMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2502A; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PAIN; CELL DESTRUCTION; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG RESPONSE; DYSPNEA; HEART VENTRICLE FAILURE; HUMAN; HUMORAL IMMUNITY; HYPERTENSION; HYPOTENSION; LIVER DYSFUNCTION; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; NAUSEA; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; RESPIRATORY DISTRESS SYNDROME; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TH1 CELL; VOMITING;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 52949085848     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.10.1553     Document Type: Article

References (37)

1. Revillion F, Bonneterre J, Peyrat JP. ErbB-2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998;34:791-808
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science 1987;235:177-82
3. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989;49:2087-90
4. Tandon AK, Clark GM, Chamness GC, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-8
5. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N EngI J Med 2001;344:783-92
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72
8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84
9. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20
10. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43
11. Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26:2999-3005
12. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26
13. Johnston S, Trudeau M, Kaufman B, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008;26:1066-72
14. Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008;19:1068-74
15. Perez P, Hoffman RW, Shaw S, et al. Specific targeting of cytotoxic T cells by and-T3 linked to anti-target cell antibody. Nature 1985;316:354-6
16. Fanger MW, Segal DM, Wunderlich JR. Going both ways: bispecific antibodies and targeted cellular cytotoxicity. FASEB J 1990;4:2846-9
17. Weiner LM, Clark JI, Ring DB, Alpaugh RK. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J Hematother 1995;4:453-6
18. Valerius T, Stockmeyer B, van Spriel AB, et al. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 1997;90;4485-92
19. Lum LG, Rathore R, Cummings F, et al. Phase I/II Study of treatment of stage IV breast cancer with OKT3 x trastuzumab-armed activated T-cells. Clin Breast Cancer 2003;4:212-7
20. Herrmann T, Grosse-Hovest L, Otz T, et al. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res 2008;68:1221-7
21. Repp R, van Ojik HH, Valerius T, et al. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer 2003;89:2234-43
22. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995;155:219-55
23. Zeidler R, Mysliwietz J, Csanady M, et al. The Fc-region. of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumor cells. Br J Cancer 2000;83:261
24. Zeidler R, Reisbach G, Wollenberg B, et al. Simultaneous activation of T-cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999;163:1246-52
25. Riesenberg R, Buchner A, Pohla. H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Hispachem Cytochem 2001;49:911-7
26. Riechelmann H, Wiesneth M, Schauwecker P, et al. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial. Cancer Immunol Immunother 2007;56:1397-406
27. Jäger M, Ruf P, Schoberth A, et al. Effect on low HER2 (1+) expressing tumor cells of the trifunctional antibody ertumaxomab [abstract 3071]. J Clin Oncol 2008;26(Suppl): 149s
28. Leidig T, Wawrsinek F, Lindemann C, Mueller-Klieser W. The trifunctional antibodies catumaxomab and ertumaxomab demonstrate efficacy in co-cultures of human multicellular tumor spheroids (MCTS) and peripheral blood mononuclear cells (PBMC) [abstract no. 399]. In: Proceedings of the 99th Annual Meeting of die American Association for Cancer Research; 12-16 April 2008; San Diego, CA
29. Lindhofer H, Menzel H, Zengerle U, et al. Bispecific antibodies effectively purge cancer cells from peripheral blood stem cell collections without affecting colony forming units. Exp Hematol 1997;25:879
30. Kiewe P, Hasmüller S, Kahlert S, et al. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006;12:3085-91
31. Heiss MM, Strohlein MA, Jáger M, et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005;117:435-43
32. Parsons SL, Murawa X, Koralewski P, et al. Intraperitoneal treatment of malignant ascites due to epithelial rumors with catumaxomab: a phase II/ III study [abstract 3000]. J Clin Oncol 2008;26(Suppl):132s
33. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001;98:2526-34
34. Borghaei H, Alpaugh RK, Bernardo P, et al. Induction of adaptive Anti-HER2/neu immune responses in a phase 1B/2 trial of 2B1 bispecific routine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group. J Immunother 2007;30:455-67
35. Weiner LM, Clark JI, Davey M, et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res 1995;55:4586-93
36. Kroesen BJ, Janssen RA, Buter J, et al. Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects. J Hematother 1995;4:409-14
37. Rusnak DW, Affeck K, Cockerill SG, et al. T'he characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001;61:7196-203